Sanofi to buy Blueprint Medicines for over $9 billion | Business

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint Medicines in a deal worth $9.1 billion (£6.7 billion) in cash, with an additional $400 million on offer in performance milestone payments.

Blueprint has one drug – Avaykyt (Avaykit in US, avapritinib) – which is approved in the US, Europe and elsewhere to treat gastrointestinal stromal tumours, as well as the rare immunological disease systemic mastocytosis. Blueprint reported 2024 sales of $479 million for the drug, with forecasts for significant growth.

The deal also brings Sanofi Blueprint’s pipeline of developmental drugs, including one in phase 2/3 clinical trials and earlier-stage projects.